Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui
Formáid:	Alt
Teanga:	English
Foilsithe / Cruthaithe:	Wiley 2021-08-01
Sraith:	ACR Open Rheumatology
Rochtain ar líne:	https://doi.org/10.1002/acr2.11259

Míreanna comhchosúla

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
de réir: Tore K Kvien, et al.
Foilsithe / Cruthaithe: (2019-05-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
de réir: Vivian P. Bykerk, et al.
Foilsithe / Cruthaithe: (2023-02-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
de réir: Jeffrey R. Curtis, et al.
Foilsithe / Cruthaithe: (2017-12-01)

Certolizumab pegol in the treatment of spondyloarthritis
de réir: Mariusz Korkosz
Foilsithe / Cruthaithe: (2014-09-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
de réir: Sh. F. Erdes
Foilsithe / Cruthaithe: (2016-02-01)

Certolizumab pegol in therapy for rheumatoid arthritis
de réir: Galina Viktorovna Lukina, et al.
Foilsithe / Cruthaithe: (2012-06-01)

Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
de réir: Marie de Bourayne, et al.
Foilsithe / Cruthaithe: (2022-02-01)

Quantitation of certolizumab pegol by validated liquid chromatography methods
de réir: Clóvis Dervil Appratto Cardoso Júnior, et al.
Foilsithe / Cruthaithe: (2023-11-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
de réir: T. V. Korotaeva, et al.
Foilsithe / Cruthaithe: (2015-10-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
de réir: Mehmet Baysal, et al.
Foilsithe / Cruthaithe: (2018-09-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
de réir: M Connock, et al.
Foilsithe / Cruthaithe: (2010-10-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
de réir: Lindsey J. Wanberg, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
de réir: Smolen, JS, et al.
Foilsithe / Cruthaithe: (2024)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
de réir: Stéphane Paul, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
de réir: Ruiz Garcia, V, et al.
Foilsithe / Cruthaithe: (2011)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
de réir: Ruiz Garcia, V, et al.
Foilsithe / Cruthaithe: (2014)

Experience with long-term use of certolizumab pegol (Cimzia)
de réir: Karine Arnoldovna Lytkina, et al.
Foilsithe / Cruthaithe: (2013-10-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
de réir: I.L. Khalif, et al.
Foilsithe / Cruthaithe: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
de réir: Ranatunga S, et al.
Foilsithe / Cruthaithe: (2014-02-01)

Experience with long-term use of certolizumab pegol (Cimzia)
de réir: Karine Arnoldovna Lytkina, et al.
Foilsithe / Cruthaithe: (2013-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
de réir: Maria Majdan, et al.
Foilsithe / Cruthaithe: (2014-07-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
de réir: Piotr Wiland, et al.
Foilsithe / Cruthaithe: (2011-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
de réir: P. I. Novikov, et al.
Foilsithe / Cruthaithe: (2018-07-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
de réir: Vera Nikolayevna Amirdjanova, et al.
Foilsithe / Cruthaithe: (2012-10-01)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
de réir: A. Spadaro, et al.
Foilsithe / Cruthaithe: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
de réir: Wojciech Blonski, et al.
Foilsithe / Cruthaithe: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
de réir: O V Knyazev, et al.
Foilsithe / Cruthaithe: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
de réir: Yael Sharon, et al.
Foilsithe / Cruthaithe: (2020-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
de réir: Tanaka, Y, et al.
Foilsithe / Cruthaithe: (2023)

Certolizumab pegol in severe hidradenitis suppurativa in pregnancy: A case report
de réir: Paolo Gisondi, et al.
Foilsithe / Cruthaithe: (2025-01-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
de réir: Evgeniy L'vovich Nasonov, et al.
Foilsithe / Cruthaithe: (2011-02-01)

Successful treatment of dissecting cellulitis with certolizumab pegol in a pregnant patient
de réir: Nouf Almuhanna, MD, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis
de réir: A. A. Kubanov, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
de réir: Henry Alistair I, et al.
Foilsithe / Cruthaithe: (2011-11-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
de réir: R. Talotta, et al.
Foilsithe / Cruthaithe: (2016-09-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
de réir: Emna Hannech, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study
de réir: Louis Bessette, et al.
Foilsithe / Cruthaithe: (2019-03-01)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
de réir: Pablo Coto-Segura, et al.
Foilsithe / Cruthaithe: (2023-09-01)

Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases
de réir: Denis Menshykau, et al.
Foilsithe / Cruthaithe: (2024-11-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
de réir: Dmitry Evgenyevich Karateev, et al.
Foilsithe / Cruthaithe: (2012-04-01)